Please assess the completion status of the following clinical trial:

Trial Title: Carbetocin at Elective Cesarean Delivery Part 2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* All patients planned for elective cesarean delivery under spinal anesthesia.~* All patients who give written informed consent to participate in this study.~Exclusion Criteria:~* All patients who refuse to give written informed consent.~* All patients who claim allergy or hypersensitivity to carbetocin or oxytocin.~* All patients with conditions that predispose to uterine atony and postpartum hemorrhage such as placenta previa, multiple gestation, preeclampsia, eclampsia, macrosomia, polyhydramnios, uterine fibroids, previous history of uterine atony and postpartum bleeding, or bleeding diathesis.~* All patients with hepatic, renal, and vascular disease,~* All patients requiring general anesthesia prior to the administration of the study drug.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Carbetocin 20mcg (Type: ACTIVE_COMPARATOR): None
- Carbetocin 40mcg (Type: ACTIVE_COMPARATOR): None
- Carbetocin 60mcg (Type: ACTIVE_COMPARATOR): None
- Carbetocin 80mcg (Type: ACTIVE_COMPARATOR): None
- Carbetocin 100mcg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).